{"schema_version":"secwatch.filing_event.v1","accession":"0001055726-25-000027","form_type":"8-K","ticker":"INO","cik":"0001055726","company_name":"INOVIO PHARMACEUTICALS, INC.","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.342062+00:00","generated_at":"2026-05-21T12:32:59.303837+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Inovio Q1 net loss narrows to $19.7M; BLA submission for INO-3107 on track for mid-2025","bullets":["Net loss narrowed to $19.7M ($0.51/share) from $30.5M ($1.31) in Q1 2024.","Cash and short-term investments $68.4M as of Mar 31, 2025, down from $94.1M at Dec 31, 2024.","On track to begin rolling BLA submission for INO-3107 (RRP) in mid-2025; FDA acceptance targeted by year-end.","DMAb Phase 1 trial: 100% of participants (24/24) at week 72 maintained antibody levels; no anti-drug antibodies.","R&D expenses decreased to $16.1M from $20.9M; net cash burn guidance ~$22M for Q2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001055726-25-000027","json":"https://secwatch.observer/filing/0001055726-25-000027.json","markdown":"https://secwatch.observer/filing/0001055726-25-000027.md","text":"https://secwatch.observer/filing/0001055726-25-000027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1055726/000105572625000027/0001055726-25-000027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1055726/000105572625000027/ino-20250513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T12:32:59.303837+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}